**Background**
Erythropoietin (EPO) is a glycoprotein hormone primarily known for its role in stimulating red blood cell production. Beyond its hematopoietic functions, EPO exhibits significant cytoprotective, neurotrophic, and angiogenic properties, making it a target of interest for treating neurological disorders and ischemic injuries. However, the use of native EPO is often limited by hematopoietic side effects, such as polycythemia. To harness the tissue-protective benefits of EPO without inducing erythropoiesis, researchers have focused on the erythropoietin/CD131 heteroreceptor. Activating this specific receptor complex can trigger protective signaling pathways without stimulating red blood cell production. In this context, we will introduce a specific agonist of the erythropoietin/CD131 heteroreceptor – Cibinetide.
**Definition**
Cibinetide (also known as ARA290) is an erythropoietin-analog peptide that acts as a specific agonist of the erythropoietin/CD131 heteroreceptor. According to the Cibinetide technical information, it is designed to provide neurotrophic and antidepressant effects without the hematopoietic side effects associated with traditional EPO.
**In Vitro and In Vivo Studies**
The Cibinetide biological activity has been demonstrated across various experimental models. In vitro, Cibinetide enhances the proliferation, migration, and resistance to $\text{H}_2\text{O}_2$-induced apoptosis of endothelial colony-forming cells (ECFCs). Regarding Cibinetide in vivo applications, a single injection of the compound following ECFC transplantation in mice with critical limb ischemia (CLI) enhanced the homing of radiolabeled transplanted cells to the ischemic leg 4 hours post-transplantation, and improved capillary density and the ischemic/non-ischemic ratio of hindlimb blood flow after 28 days.
In metabolic research, Cibinetide (30 $\mu\text{g/kg}$, s.c.) was shown to prevent the progressive worsening of glucose control in Goto-Kakizaki (GK) rats and significantly decreased glucose AUCs in intraperitoneal glucose tolerance tests (IPGTT) without affecting body weight. Furthermore, in rats with experimental autoimmune encephalomyelitis (EAE), Cibinetide treatment showed dose-dependent therapeutic effects; while a low dose (35 $\mu\text{g/kg}$, i.p.) only slightly attenuated severity, a higher dose (70 $\mu\text{g/kg}$, i.p.) significantly delayed disease onset, decreased neurologic severity, and shortened the duration of EAE. In conclusion, Cibinetide is a nonerythropoietic EPO-analog peptide with potential applications in treating ischemic, metabolic, and neurological disorders.
Keywords
Cibinetide, 1208243-50-8, ARA290, ARA 290, ARA-290, Transmembrane Glycoprotein, Inhibitor, inhibitor, inhibit
References
[1] Hache G, et al. ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors’ Angiogenic Potential and Homing Ability. Shock. 2016 Oct;46(4):390-7
[2] Carole Muller, et al. ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats. Mol Med. 2015; 21(1): 969–978
[3] Chen H, et al. Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat. J Neuroimmunol. 2014 Mar 15;268(1-2):64-70